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The management of localized prostate cancer is challenging because of the many therapeu-
tic options available, none of which is generally acknowledged as superior to the others in
every respect. The selection of the most appropriate treatment should therefore reflect
patients’ preferences.
Objective
The purpose of the following study was to pilot a new approach for investigating whether
urologists who had previously provided patients with therapeutic advice actually knew their
patients’ importance weights concerning the relevant aspects of the treatments at issue.
Method
Participants were patients recently diagnosed with localized prostate cancer (n = 20), urolo-
gists (n = 10), and non-medical professionals (architects, n = 10). These last served as a
control group for the urologists and were matched to them for age and gender. Patients’
importance weights were elicited by two standard methods (Direct Rating and Value Hierar-
chy). Each urologist was asked to estimate (with Direct Rating) his/her patient’s importance
weights. The same task was performed by a corresponding architect, who never met the
patient and knew only the patient’s age. Univariate and bivariate statistical analyses were
performed to investigate the association between importance weights as elicited from
patients and as estimated by urologists and architects, as well as to assess whether such
agreement was attribute-dependent.
Results
Participants found both elicitation methods easy to use. The correlation between patients’
actual importance weights and urologists’ estimates was poor and comparable to that
obtained between patients and architects. This result did not depend on the attribute
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considered, with the sole exception of the attribute “Effectiveness in curing the cancer”,
which was evaluated as the most important attribute by the majority of participants.
Conclusion
These findings demonstrate the feasibility of the employed methodology and highlight the
need to support preference-sensitive decisions in clinical practice by facilitating the elicita-
tion of patients’ importance weights, as well as their communication to physicians.
Introduction
Some medical decisions are clear-cut because there is an effective gold standard that does not
have major drawbacks. In other situations, significant trade-offs have to be made among all
relevant aspects of the available options (e.g., benefits vs. side effects of competing treatments).
In these cases, personal considerations can make a difference, and, given the same health con-
ditions, what is better for one individual is not necessarily so for others. Involving patients in
such preference-sensitive decisions has been widely advocated, especially in the case of life-
threatening illnesses and/or treatments with risky outcomes [1–5]. It is not just a matter of eth-
ics: patient participation has been shown to be associated with better understanding of medical
information, increased satisfaction with care, greater adherence to therapy, improved health
outcomes, lower anxiety and discomfort, as well as reduced costs of care [5–8]. However,
despite general agreement on the importance of engaging patients in active decision making
about their health care, and despite efforts to educate them in how to play this role, implemen-
tation has proved challenging [9–15]. Furthermore, patients differ widely in the extent to
which they feel comfortable with being in control of their own health decisions, depending on
various factors, such as their mastery of medical terms and concepts, physical and cognitive
ability, emotional state, beliefs, previous experiences with health services, and last but not least,
their perception of the adequacy of information received [12,16–19]. In the end, although
most patients today are less likely to delegate medical decisions, they do make their choices
after seriously considering their physicians’ recommendations [20–23]. It therefore appears
important to determine how well-informed these recommendations are when it comes to
preference-sensitive decisions. The present study is aimed at proposing a new procedure for
enhancing the understanding of this topic through a focus on treatment decisions for clinically
localized prostate cancer.
Prostate cancer (hereinafter, PCa) is one of the most common cancers among adult males
[24,25], and a leading cause of cancer-related death, both in the USA [26] and Europe [27].
Clinically localized PCa is a good case study for our purposes in two ways. The first is the large
number of available treatment options (including active surveillance, radical or nerve-sparing
prostatectomy, external beam radiation therapy, brachytherapy, cryosurgery, and hormonal
therapies), none of which is acknowledged by experts as the optimal choice in every respect for
all patients [28]. Indeed, mortality rates associated with the various treatments are not signifi-
cantly different [29], and each can involve significant side effects on quality of life [24,30], thus
making this choice an exemplary (“archetypal,” [31]) preference-sensitive decision. The sec-
ond reason to focus on clinically localized PCa is that older males newly diagnosed with cancer
(especially those with a lower level of education) are among the patients most reluctant to
engage in active decision making concerning their health [6,18,20,32–34]. This finding is in
line with the results of various studies showing a major role of physicians in treatment
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decisions concerning clinically localized PCa: patients are not always given the opportunity to
discuss their inclinations during clinical appointments and are more likely to receive the treat-
ment favored or best known by their physician [35–41].
Even assuming physicians were capable of prioritizing patients’ preferences over what
they think is in the patients’ best interest (itself not an easy task, as pointed out in [42]), it is
unclear whether physicians actually know what patients with clinically localized PCa actually
prefer. Somewhat surprisingly, there is not much earlier empirical work on this matter. A
few studies have focused on specific aspects of the PCa treatment decision process and
found, for example, that physicians’ substitute preferences and recommendations were
strongly driven by their own inclinations and/or medical factors (such as patients’ age and
Gleason score), to the detriment of patients’ interests in the less-toxic treatment [43] or in
remaining sexually active [39]. In what is, to our knowledge, the most systematic study on
the subject, Elstein and collaborators [44,45] documented scant agreement between physi-
cians and patients on specific components of a multi-attribute model of localized PCa.
Newly diagnosed patients had to both evaluate the utilities of selected health states and rank
the importance of a number of attributes on which these health states were defined. Physi-
cians had to provide their views of which utilities and importance rankings would be in the
patients’ best interest. For both health states and attributes, the patient-physician correla-
tions were variable and, in general, lower than the critical value (.8) that could justify substi-
tuted judgment, according to Elstein et al. [44,45].
While related to the previous investigations that examined physicians’ awareness of local-
ized PCa patients’ preferences, the approach proposed in the present study differs from them
in some important respects. First, we were interested in analytically exploring the importance
of an extensive set of attributes rather than only a few isolated aspects (e.g., preservation of sex-
ual function). Second, our focus was on treatment options rather than health states. We concur
with Elstein et al. [44,45] that the desirability of various health states may affect patients’ treat-
ment decisions, yet the two kinds of assessment have different implications. Indeed, even a
perfect patient-physician agreement on health states would be fully compatible with different
treatment choices if important aspects of the available treatments (e.g., their duration) were
missing from the health state evaluation. Symmetrically, a strong disagreement on health states
would not necessarily translate into different treatment choices, since the available treatments
may be indistinguishable with respect to these states. For these reasons, we selected a set of
attributes that allow direct and comparative assessment of the most common treatments for
clinically localized PCa (a detailed description of the attributes, as well as an explanation of
their structure, is provided in the Materials section and in S1 Appendix). The third major dif-
ference with previous studies is that the agreement between patients and physicians was evalu-
ated by comparing it, in addition to a threshold, with the agreement obtained between patients
and a control group of non-medical professionals who had no knowledge of the patients and
were unfamiliar with PCa treatments. We think that such a control group of participants pro-
vides a suitable benchmark to evaluate the goodness of physicians’ estimates, since one can rea-
sonably assume that these non-expert participants, who were blind to patients, were clearly
unqualified to advise patients on their treatment decisions. The fourth and most important
difference concerns the type of judgment elicited from physicians. Previous studies [43–45]
showed that patients’ and physicians’ evaluations may diverge. However, this does not auto-
matically translate into a disregard of patients’ preferences, especially because the medical
community acknowledges that clinically localized PCa treatment decisions ought to reflect
patients’ personal values. Accordingly, we did not measure the agreement between patients’
and physicians’ weights, but rather the agreement between patients’ weights and physicians’
estimates of those same weights. This allowed us to quantify the physicians’ awareness of their
Mind the gap: Physicians’ assessment of patients’ importance weights
PLOS ONE | https://doi.org/10.1371/journal.pone.0200780 July 26, 2018 3 / 13
patients’ preferences independently of their own opinions, whether in application to them-
selves or in consideration of their patients’ best interest.
Methods
Participants
Participants in this study comprised 20 patients, 10 physicians, and 10 non-medical profes-
sionals. The patient group consisted of 20 men, mean age 67 years (SD = 7), newly diagnosed
(i.e., within the preceding 4 weeks) with clinically localized PCa, staging T1-2N0M0. Patients
had not yet started any treatment, had no significant comorbidities, and had a life expectancy
greater than 10 years. Physicians were 10 urologists (2 female and 8 male), mean age 50 years
(SD = 9), working at the urology units of two main clinical facilities in northeast Italy. Finally,
the non-medical professional group consisted of 10 architects (2 female and 8 male), mean age
45 years (SD = 8).
Ethics statement. The study was approved by the research ethics committee of the APSS
(the regional healthcare provider within the Provincia Autonoma di Trento, Italy). Written
informed consent was obtained from all individual participants included in the study. All pro-
cedures were in accordance with the Helsinki declaration.
Material
In accordance with the guidelines of Multiple Criteria Decision Analysis for Health Care [46],
we generated our list of attributes so as to satisfy the following desiderata: to capture the com-
plexity of the available clinically localized PCa treatments (completeness), to include only rele-
vant and no double-counted attributes for the purposes of comparing existing PCa treatments
(non-redundancy and non-overlapping), and to ensure that the values of one attribute would
not affect, nor would they depend on, the values of other attributes (mutual preferential inde-
pendence, see also [47,48]). This last is a fundamental condition of multi-attribute utility theory
that prevents the interaction between attributes and allows the additive decomposition of the
utility function. Its fulfillment was made easier by our focus on treatments rather than health
states, since the values of treatments (e.g., their expected effectiveness or side effects) are typi-
cally fixed and independent from each other, while the same does not hold for most attributes
expressing how the patient feels (e.g., mood or pain, as used in [44,45]). Overall, our analysis
generated eight attributes pertaining to four macro-dimensions, as described in Table 1.
Each attribute was accompanied by a short description that included a specification of its
worst and best levels (see S1 Appendix). This was motivated by the consideration that impor-
tance weights depend on the ranges of attributes [49]. Such clarification also helped us make
Table 1. Attributes of the treatments.
Macro-dimensions Attributes
Effectiveness Effectiveness in curing the cancer
Effectiveness in curing cancer-related disorders (e.g. as urge in urination,
muscle tension, . . .)
Tolerability Duration
Discomfort (e.g., hospitalization, pain, . . .)
Temporary side effects Temporary urinary problems
Temporary digestive problems
Permanent side effects and/or
complications
Permanent erectile dysfunction
Other permanent problems (e.g., anesthesia-related complications, . . .)
https://doi.org/10.1371/journal.pone.0200780.t001
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the attributes more understandable to patients and architects, who might otherwise be unfa-
miliar with this decision problem. It also indirectly confirmed that our list of attributes made
sense to physicians, given that none of them raised any concerns. Attributes were presented to
participants in two different orders (a randomly chosen one and its reverse). The attributes
were presented to each patient-urologist/patient-architect pair in the same order.
Procedure
Patients were assigned to urologists by the hospital administration based on the timing of the
outcome of the biopsy and on the urologists’ shift schedule. Data were collected only after at
least one meeting between urologist and patient, during which the urologist had informed the
patient about the positive biopsy result, discussed with him the treatment options, and pro-
vided him with his/her own treatment advice. Since physicians were interviewed only after
they had already advised a patient with a specific treatment, it seems reasonable to assume that
they should have been aware of the patient’s importance weights. To minimize possible mem-
ory interference, each half of the urologist-patient pair was interviewed within three days of
the other, without any other encounter taking place between the two in the meantime. Even
within such a small time window, whenever a urologist raised a concern about her/his memory
of a specific patient whose importance weights s/he had been asked to estimate, we did not
force her/him and simply did not include that pair in our data collection. This reduced the
number of participants, but it also helped us to avoid interference with normal clinical activity.
In particular, it attenuated the risk that urologists would alter their patterns of practice with
patients due to their anticipation of our questionnaire. Each architect was matched for age and
gender to a unique physician and was paired with the same patient(s). Architects never met
the patients; they were told only a patient’s age and that he had received a recent diagnosis of
clinically localized PCa.
After being introduced to the eight attributes, participants were asked to provide their judg-
ments, that is, importance weights for patients and estimates of patients’ importance weights
for urologists and architects. More specifically, participants in all three groups (patients, urolo-
gists, and architects) were asked to rate each attribute independently on a scale ranging from 0
(= “not important at all”) to 100 (= “extremely important”). This elicitation method is known as
Direct Rating (hereinafter DR, [50]) and is a simple technique with relatively low demands on
time. For patients only, we also employed a version of the Hierarchical Point Allocation tech-
nique known as Value Hierarchy (hereinafter VH, [51]), in which the attributes are grouped
into fewer macro-dimensions (in our case, the eight attributes were arranged in pairs into four
macro-dimensions, see Table 1); participants have to distribute 100 importance points among
the macro-dimensions (in our case, four, as in Table 1) and then, they have to further distribute
100 importance points between the attributes within each macro-dimension (two in our case).
Importance weights are calculated by aggregating the two judgments and rescaling the result
(i.e., by multiplying the within- and between-dimension point scores obtained for each attri-
bute, and dividing the result by 100). Given that hierarchical techniques involve a number of
pairwise comparisons, they are supposed to reflect people’s propensity for relative judgments,
as well as to help them organize complex goal structures into hierarchical clusters [52]. Patients’
weights were elicited first with DR and then with VH. We decided to use only DR with urolo-
gists because they were already familiar with the structure of the attributes under consideration
and, furthermore, because it was not realistic for them to complete a lengthy interview during
their working hours. On the other hand, the use of two different techniques with patients
allowed us to assess the consistency of results. Indeed, although both methods yield a cardinal
scale of importance, DR reportedly yields a lower spread of weights than VH [49].
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Statistical analysis
We performed descriptive statistics first, in order to summarize patients’ importance weights
for each attribute. The general agreement between patients’ importance weights and their esti-
mates as provided by urologists and architects was assessed by computing Kendall rank-order
correlations. To determine whether these correlations exceeded the critical value of .8, one-
sample t-tests were performed. Paired t-tests were used to determine if the agreement with
patients’ importance weights differed significantly between urologists and architects. To quan-
tify the evidence in support of the null hypothesis in these two comparisons, we computed the
corresponding Bayes factors (using JASP 0.7.5.6; www.jasp-stats.org). We also converted par-
ticipants’ judgements into ranks and, for each attribute, determined by means of a binomial
test whether urologists’ and architects’ ranks in agreement with patients’ ranks significantly
exceeded those in disagreement. Finally, we assessed by Kendall rank-order correlations the
within-subject agreement in patients’ weights elicited using the two DR and VH methods.
Results
Patients’ mean importance weights for each attribute are reported in Table 2. Unsurprisingly,
“Effectiveness in curing the cancer” was the most important attribute (whatever the method
used to elicit weights), while the lowest weights were given to “Discomfort” and “Temporary
digestive problems” (with DR and VH method, respectively).
As shown in Table 3, the overall agreement between patients and urologists across the eight
attributes was poor, regardless of the method used to elicit importance weights with patients
Table 2. Patients’ mean importance weights (and standard deviation) for each attribute.
Attribute DR VH
M (SD) M (SD)
Effectiveness in curing the cancer 21 (6) 40 (11)
Effectiveness in curing cancer-related disorders 12 (7) 9 (6)
Duration 12 (6) 8 (5)
Discomfort 9 (5) 8 (5)
Temporary urinary problems 14 (5) 7 (4)
Temporary digestive problems 10 (5) 5 (3)
Permanent erectile dysfunction 11 (5) 12 (7)
Other permanent problems 13 (7) 13 (7)
Weights are on a scale from 0 (= “not important at all”) to 100 (= “extremely important”). In order to make the
weights obtained with the two methods comparable, those elicited with DR have been normalized to sum to 100.
https://doi.org/10.1371/journal.pone.0200780.t002
Table 3. Mean, median, and range of the Kendall’s τ coefficients between patients and urologists and between patients and architects.
Statistics Patients (DR) Patients (VH)
Urologists (DR) Architects (DR) Urologists (DR) Architects (DR)
Ma .33 .29 .34 .25
Mdna .27 .32 .37 .30
Rangea .06/.61 -.04/.60 -.17/.69 -.34/.64
t-test t(9) = .49, p = .632 t(9) = .73, p = .483
BF01 2.92 2.59
a Mean, median, and range values were taken before Fisher Z transformation of the correlation coefficients.
https://doi.org/10.1371/journal.pone.0200780.t003
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(Kendall’s tau, M = .33, Md = .27, and M = .34, Md = .37, for DR and VH method, respec-
tively). Similar figures were obtained for the agreement between patients and architects (Ken-
dall’s tau, M = .29, Md = .32, and M = .25, Md = .30, for patients’ weights elicited using the DR
and VH method, respectively). (Note that, although we had 20 patient-urologist/patient-archi-
tect pairs, the above statistics employ only 10 values each because, whenever a urologist and
the corresponding architect estimated the importance weights of multiple patients, the mean
correlation coefficient was considered.)
In order to run inferential statistics, we applied a Fisher Z transformation to normalize the
distribution of correlation coefficients. The agreement between patients and urologists was
revealed to be significantly lower than .8, the “high-enough” cut-off in correlation proposed by
Elstein et al. [45], t(9) = -5.99, p< .001, t(9) = -3.87, p = .004, for patients’ weights elicited
using the DR and VH methods, respectively. A second analysis of the accuracy of urologists’
estimates of patients’ importance weights was made by comparing the agreements in patient-
urologist and in patient-architect pairs. These did not significantly differ, according to two
paired t-tests [t(9) = .49, p = .632 and t(9) = .73, p = .483, for patients’ weights elicited using the
DR and VH methods, respectively]. Bayes factor analysis indicated that the obtained data were
2.92 and 2.59 times more likely to occur under the null hypothesis compared to the alternative
hypothesis (when patients’ importance weights were elicited by the DR and the VH methods,
respectively).
To quantify the agreement on each attribute, we converted all participants’ judgments
into ranks and then compared these ranks within all patient-urologist and patient-architect
pairs. In particular, for each attribute, we considered two ranks to be in agreement if and
only if they differed by at most one position. For example, suppose that the attribute “Effec-
tiveness in curing cancer-related disorders” was second in a patient’s ranking. If the same
attribute had a rank between 1 and 3 in his urologist’s evaluation, the two ranks were consid-
ered to be in agreement—otherwise they were not. Finally, we computed the fraction of
ranks in agreement (see Table 4). (Again, whenever a urologist and corresponding architect
estimated the importance weights of multiple patients, the mean fraction of agreement was
considered.)
The agreement in rankings between patients and both urologist and architects was generally
poor, regardless of the attribute. The sole exception is represented by the attribute “Effective-
ness in curing the cancer”, for which the ranks in agreement significantly exceeded those in
disagreement for all but the patient-urologist pairs in which patients’ weights were elicited
using the DR method (ps = .021 and p = .109, binomial test, respectively).
Table 4. Fraction of ranks in agreement between patients and urologists and between patients and architects for each attribute.
Attribute Patient DR Patient VH
Urologist DR Architect DR Urologist DR Architect DR
Effectiveness in curing the cancer .74 .88 .86 .90
Effectiveness in curing cancer-related disorders .27 .62 .35 .52
Duration .22 .26 .48 .18
Discomfort .47 .37 .29 .25
Temporary urinary problems .22 .24 .18 .27
Temporary digestive problems .39 .36 .46 .44
Permanent erectile dysfunction .22 .41 .12 .45
Other permanent problems .45 .32 .52 .21
 Significantly greater than 0.5 according to a binomial test (p< .05).
https://doi.org/10.1371/journal.pone.0200780.t004
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Finally, the within-subject agreement in patients’ weights elicited using the DR and VH
methods was moderate (Kendall’s tau, M = .55, SD = .29). This might be because, as reported
in the literature, the distribution of weights elicited by VH had greater spread than those from
DR (coefficients of variations = .98 and .51, for weights elicited using the VH and DR methods,
respectively, F(318) = 18.3, p< .001).
Discussion
Traditionally, theoretical and empirical research on physician-patient communication has
focused on how to improve the flow of information from the former to the latter [7,53–57].
Patients’ understanding of medical terms and concepts, including the pros and cons of avail-
able treatments, as well as relevant statistical information, is no doubt needed to help them be
fully informed and actively involved in their own care. However, when it comes to preference-
sensitive decisions, this is not enough. Preference-sensitive decisions involve at least two
experts: the physician, who masters the clinical evidence, and the patient, who knows better
what matters most to him. Unless one makes the unrealistic assumption that, once informed,
patients decide among the available treatments with complete autonomy, their relevant prefer-
ences should be shared with physicians.
In this study, we piloted and demonstrated the feasibility of a new methodological approach
to determine whether patients’ importance weights are effectively conveyed from patients to
physicians. Our results, although referring to a limited number of participants, suggest that
urologists’ accuracy in estimating these weights was poor and not significantly greater than
that of non-medical professionals who had never met the patients and knew only their ages,
regardless of the elicitation method used. This was in spite of the fact that urologists felt confi-
dent enough to provide patients a precise therapeutic recommendation. With respect to earlier
results, this finding provides more direct evidence of a dearth of communication between
patients and physicians, because it clarifies that their possible disagreements in treatment
choice may reflect not only a difference in opinion but also physicians’ lack of awareness of
what patients prefer.
The reasons for the information gap between PCa patients and urologists about relevant
importance weights fall outside the scope of this study and represent an interesting matter for
future research. Our preliminary results along with those mentioned in the Introduction sug-
gest that the problem may stem from the structure of patient-physician encounters (which are
typically physician-driven) and from the difficulty of inferring others’ importance weights. It
has been claimed that physicians need help in determining patient preferences [43], but how
this help should be given is far from obvious. Indeed, according to two recent reviews [57,58],
most existing decision aids for localized PCa fail to demonstrate substantial benefits, because
they tend to provide patients with detailed information about the features of available treat-
ments rather than addressing personal importance. A more advanced generation of decision
tools, known as Explicit Values Clarification Methods [59–61], has been developed in order to
help patients determine what matters most to them. However, there are no established best
practices, and most of the techniques that have been used do not have a clear theoretical or
empirical grounding [60]. Multiple Criteria Decision Analysis may guide new strategies for
improving physicians’ accessibility to patients’ preferences by suggesting concrete means with
which to elicit and share decision weights. For example, one possibility might be to implement
a routine practice in which the treatment options are briefly introduced to patients along with
an extensive description of their relevant attributes. Once the content and ranges of these attri-
butes have been fully explained, patients could fill in a grid with their importance weights. Phy-
sicians could then describe more precisely how well the available treatments perform on each
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attribute and start collecting patients’ opinions on the attractiveness (or unattractiveness) of
various treatments. Finally, patients’ overall assessments could be contrasted with the results of
the weight elicitation procedure. When the evaluations are consistent, it would give all parties
reassurance that patients have understood the medical information received and have effec-
tively voiced their preferences. Otherwise, it would indicate that clarification and/or a more
in-depth evaluation is required. Either way, it would assist physicians in understanding
patients’ priorities and would provide them with a sound basis for possible recommendations.
We expect that not only the treatment choice but also the overall medical relationship could
benefit from a systematized elicitation of importance weights, since it could foster patients’
feelings that the treatment is personalized, with a consequent increase in compliance and satis-
faction [62,63]. Note also that a similar procedure could be generalized beyond the PCa treat-
ment dilemma to other kinds of preference-sensitive medical decisions.
Future large-scale empirical studies aimed at quantifying physicians’ awareness of patients’
importance weights or facilitating the elicitation and sharing of patients’ preferences might
also consider some other methodological open issues. First, to date there has been little empiri-
cal work on the effects and robustness of various preference-elicitation procedures, especially
in the medical field. The modest correlation between the DR and VH methods found in this
study suggests it might be worth exploring this topic more thoroughly by analyzing which elic-
itation procedure could best capture patients’ importance weights in terms of coherence and
test-retest reliability—all without imposing an excessive cognitive burden. Another relevant
and still unexplored issue concerns the consistency of weight measurements over a long time
span. We elicited patients’ importance weights between diagnosis and treatment choice. This
enabled us to prevent the distortion in preference that typically follows important decisions
(like those generated by consolidation processes [64]), as well as to avoid potential confounds
that might be introduced by the consequences of ongoing treatments, in particular the out-
comes of care. However, some of the attributes that we considered (e.g., those referring to
permanent conditions, like erectile dysfunction) also concern the distant future, and their eval-
uation may change in the course of the illness or upon its cure [65]. Accordingly, it might well
be that the corresponding weights could be over- or under-estimated when choosing the treat-
ment. Indeed, a number of studies have shown that people tend to make various errors when
predicting their future preferences and feelings (a phenomenon known as faulty affective fore-
casting; for more on this, see [66–68]), with potentially strong implications for medical deci-
sion making. In principle, the observed gap could be accounted for, at least partially, by
assuming that experienced physicians may have a better idea of what their patients would pre-
fer in the long run than the patients have themselves. Longitudinal research is required to
investigate this possibility and how importance weights may change over time, so that patients’
successive relevant preferences can be included in their treatment choices. Finally, future
research could more thoroughly address the relationship between importance weights and
choice. Knowing the relevant importance weights is a necessary but not sufficient condition
for identifying the best treatment. Other factors may affect the preferences. For example, a
patient may well decide to disregard all treatments whose values fall below a threshold on
some crucial attribute, while being happy to compare the remaining options by summing their
weighted values across the attributes. To the best of our knowledge, this compelling research
topic has not been fully explored in the medical literature on preference-sensitive decisions.
Conclusion
The results of this pilot study suggest that, although urologists typically have an active role in
PCa treatment decisions, they may not be aware of patients’ importance weights concerning
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the relevant dimensions of the available options. While awaiting the results of more definitive
studies, we might consider why this happens and how we could change routine procedures to
facilitate the elicitation and sharing of this kind of information. At present, the laws of many
Western countries grant patients the right to consent to or refuse the treatments that physi-
cians recommend, yet they do not require the physicians to elicit patients’ preferences or to
support them in a process of deliberation (see [5]). Interestingly, this does not hold for invest-
ment advisors, who are required to make a reliable assessment of their clients’ risk profile and
financial objectives before providing them with suggestions (see the suitability requirements of
the Markets in Financial Instruments MiFID II—Directive 2014/65/EU [69]). Unless we con-
sider uninformed recommendations concerning health less problematic, similar measures in
healthcare settings seem worthy of consideration.
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